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INTRODUCTION
Polycystic liver is the most common extra-renal manifesta-
tion associated with autososmal dominant polycystic kidney
disease (ADPKD), presenting in 78.4% of all ADPKD pa-
tients (71.7% in male, 83.1% in female) in Korea (1). Most
ADPKD patients with polycystic liver are asymptomatic
and require no treatment. However, recently hepatic symp-
toms have become more frequent because of lengthened lifes-
pan of ADPKD patients, and patients with polycystic liver
often suffer from abdominal discomfort, dyspepsia, or dysp-
nea. Several interventions have been tried to relieve these
symptoms, including percutaneous cyst aspiration with scle-
rosis, laparoscopic fenestration, open surgical cyst fenestra-
tion, partial hepatectomy, and hepatic transplantation (2).
Percutaneous cyst aspiration with sclerosis and laparoscopic
fenestration are limited to patients with one or a few very
large cysts (3, 4). On the other hand, patients with multiple
small cysts can benefit from open surgical cyst fenestration
or partial hepatectomy. However, these methods cannot be
used for patients with poor nutritional status, massive ascites,
or renal failure. Liver transplantation is the best method to
solve the problem. But, there are not enough eligible cadav-
eric donors in Korea. Moreover, surgical procedures would
result in morbidity and mortality, reported as high as 42 per-
cent (2, 5). 
Recently, Ubara et al. successfully treated symptomatic
patients with polycystic liver by selective transcatheter arte-
rial embolization (TAE) of hepatic arteries (6, 7). TAE was
developed initially for treating hypervascular hepatocellular
carcinoma. They focused on the point that hepatic cysts in
ADPKD patients are mostly supplied from hepatic arteries
but not from portal veins (8). Therefore, they successfully
embolized hepatic artery branches that supply major hepat-
ic cysts, leading to shrinkage of the cyst and liver size. There
have been only few complications after embolization.
We noticed TAE could be an effective and safe way to relieve
mass effects of polycystic liver. Therefore, we designed a pilot
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Accepted : 22 May 2008study to evaluate the effectiveness and complications of TAE
for massive polycystic liver in ADPKD patients. Four AD-
PKD patients with symptomatic liver cysts were enrolled
in the study, and the results in three patients were analyzed
12 months after procedure. 
MATERIALS AND METHODS
This pilot study was designed to relieve severe symptoms
caused by massive polycystic liver. Therefore, ADPKD pa-
tients with severe symptoms such as ascites, leg edema, dys-
pepsia, malnutrition or chronic disabling pain not relieved
with medical treatment and those who were not able to re-
ceive surgical procedures due to poor medical condition were
included. All patients were diagnosed and managed in poly-
cystic kidney disease (PKD) clinic, Seoul National Univer-
sity Hospital. ADPKD patients with chronic liver disease
or those with aspartate aminotransferase (AST) or alanine
aminotransferase (ALT) higher than 80 IU/L, those with allergy
to contrast media, or those with liver cyst infection or other
systemic infection were excluded from the study. We obtained
approval from our hospital ethics committee for evaluation
of a new treatment for symptomatic enlarged polycystic liver.
From September 2005 to February 2006, four patients were
enrolled in the study and hepatic TAE was performed. After
getting informed consent, all patients underwent multipha-
sic contrast enhanced computed tomography (CT) of the liver
before TAE and 12 months after TAE using a multi-detec-
tor CT scanner. CT examination was performed using a spi-
ral technique with 1.25- to 2.5-mm collimation and 1-mm
reconstruction intervals. The protocol for liver CT required
a total volume of 150 mL of nonionic intravenous contrast
material (Ultravist, Schering AG, Berlin, Germany; concen-
tration, 370 mg/mL), administered by power injection at a
rate of 4 mL/s, and scanned using a bolus-tracking technique.
To optimize hepatic arterial enhancement, after injection of
contrast material, an auto-triggering technique was used from
the aorta at the level of celiac artery. The hepatic arterial phase
scan was obtained 6 sec after 100 Hounsfield Units (HU). The
portal venous phase scan was obtained 65 sec after contrast
administration. The thin-section images were transferred to
Rapidia workstation (Infinitt, Seoul, Korea) for three-dimen-
sional reconstruction to calculate liver and cyst volumes.
After common femoral artery puncture, celiac axis arteriog-
raphy was performed by selective catheterization of the celi-
ac axis using a 5-Fr angiographic catheter (RH; Cook, Bloom-
ington, IN, U.S.A.). To precisely define peripheral hepatic
arterial anatomy, additional super-selective hepatic arteriogra-
phies using a 3-Fr micro-catheter (Microferret; Cook) were
performed. Two interventional radiologists interpreted the
angiograms and CT images in consensus to decide the target
arteries and extent of embolization. Liver is divided into 8
segments. We intended to embolize the hepatic artery supply-
ing the dominant hepatic segments replaced by cysts. Embo-
lized hepatic segments in each patient are listed in Table 3.
Targets for TAE included 5 segments in 3 patients, 4 segments
in 1 patient.
After super-selective catheterization of the target artery,
polyvinyl alcohol (PVA) particles (Contour; Boston Scientific,
Natick, MA, U.S.A.), which range in size from 150 to 250
μ m, were used as initial embolic materials for embolization.
Injections of PVA particles were performed under direct flu-
oroscopic visualization until the stasis of contrast material in
the target artery. Then, the tip of micro-catheter was advanced
as far as possible in the target artery and further embolization
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Fig. 1. Transcatheter arterial embolization of selective hepatic artery using PVA particles and micro-coils (Case No.1).
A Bwas performed with micro-coils (Micronester; Cook) to occlude
the target artery completely (Fig. 1). Coils were 3-4 mm in
diameter and 14 cm in length. After embolization, celiac
axis arteriography was performed to confirm the complete
occlusion of the target artery. TAE was performed only once
in every patient, and the mean number of micro-coils used
for TAE was 16.25 (range, 10 to 24). 
All patients were asked for any change in symptom or sub-
jective feelings after procedure. Also we analyzed any adverse
effects occurred during the study.
RESULTS
Patient characteristics
Four patients were enrolled in the study and one patient
was lost in follow up after TAE. Therefore, the results in three
patients were analyzed. All patients were women with a mean
age of 60 yr, ranging from 47 to 71 yr. All of them had severe
digestive symptoms related to enlarged liver cysts before TAE,
including abdominal pain, nausea, or dyspepsia. One patient
also complained of dyspnea (Table 1). These symptoms were
intractable even after medical treatment. 
Improvement of subjective symptoms
Although no significant improvements were reported im-
mediately after TAE, abdominal discomfort, dyspepsia, and
dyspnea were much improved twelve months after TAE.
When we evaluated them a year after TAE, two out of three
patients regained weight without increased ascites. Nutri-
tional status also improved after TAE, showing improve-
ment in cholesterol and albumin level (Table 2).
Total liver and liver cyst volumes 
Total liver volume before hepatic TAE was 9,435, 6,872,
and 12,164 cm3. Twelve months after TAE, liver volume had
decreased to 6,316, 6,718, and 10,921 cm3respectively, show-
ing as much as 33.1% reduction from pretreatment liver
volume (Fig. 2, 3). Total volume of hepatic cysts also decreased
in two cases but did not change in one case. Total intra-hep-
atic cyst volume before TAE was 6,076, 2,839, and 8,184
cm3, and 3,906, 2,892, and 6,131 cm3 respectively twelve
months after TAE. TAE was effective in reducing cyst vol-
ume, showing as much as 47.7% reduction from pretreat-
ment cyst volume. 
We also calculated the volume of remaining parenchyma
by subtracting the cyst volume from the total liver volume.
TAE for Massive Polycystic Liver in ADPKD 59
TAE, transcatheter arterial embolization; IVC, Inferior vena cava; RUQ,
right upper quadrant; HD, hemodialysis; BMI, Body mass index.
TAE, transcatheter arterial embolization; mo, months.  
No. Type Previous 
treatment
Pre-TAE symptom
Renal
function
BMI
1 63 Sclerotherapy #3 Ascites, dyspepsia, Cr 1.4  26.71
nausea, IVC  mg/dL
compression, 
RUQ pain 
2 71 None Abdominal pain,  on HD 28.71
ascites, back pain,
dyspnea, IVC 
compression, 
umbilical hernia
3 47 None Abdominal fullness,  Cr 1.5 30.03
back pain, epigastric  mg/dL
soreness
Table 1. Patient characteristics
No.
Body weight (kg)
0 mo 3 mo 12 mo
Albumin (g/dL)
0 mo 3 mo 12 mo
Cholesterol (mg/dL)
0 mo 3 mo 12 mo
1 65.0 57.5 61.5 113 123 129 3.1 3.4 4.0
2 78.8 72.0 74.4 165 154 168 3.4 3.8 3.7
3 64.6 60.5 58.7 118 144 97 2.5 2.6 2.4
Table 2. Changes in body weights and nutritional markers after
TAE
A
Pre-TAE
B
Post-TAE (12-months later)
Fig. 2. Representative computed tomographic images (Case No.1).
(A) Before hepatic TAE, this patient’s total liver, intra-hepatic cyst,
and hepatic parenchymal volumes were 9,435, 6,076, and 3,359
cm
3, respectively. Hepatic cysts were numerous and limited to hep-
atic segment 1, 3, 4, 5, 8. (B) The same patient 12 months after
hepatic TAE. Total liver and intra-hepatic cyst volumes decreased
to 6,316 and 3,906 cm
3, respectively. Hepatic parenchymal vol-
ume also decreased to 2,410 cm
3 in this patient. Total parenchymal volume changed from 3,359, 4,033, 3,980
cm3 to 2,410, 3,826, and 4,790 cm3, respectively. In the last
case, the parenchymal volume increased by 20%.
Immediate complications after hepatic TAE 
The first patient was hospitalized for 8 days after TAE
because of febrile condition and abdominal discomfort. Fever
rose up to 38.2℃without chills and subsided without antibi-
otics uses after four days. In the second case, the patient was
hospitalized for 18 days after procedure, about a week due to
procedure-related fever and the other 10 days for non-proce-
dure-related medical problem such as phlebitis. Fever rose
up to 39.8℃ with chilling sense immediately after proce-
dure. Moderate to severe epigastric pain and back pain were
accompanied. We used empirical antibiotics for 2 weeks, but
culture study revealed negative result. Pain was controlled
with opioid analgesics and subsided in 5 days after TAE.
The third patient was hospitalized for 8 days after procedure
because of fever, abdominal pain, nausea, and constipation.
Fever occurred two days after TAE up to 39.3℃. Fever was
subsided within 1 week of empirical antibiotic therapy. As
same as the first case, culture study revealed negative result.
Severe nausea and vomiting were controlled with anti-emet-
ics. Mild elevation in AST and ALT was shown in patients
immediately after TAE but returned to the normal range in 8
days.
DISCUSSION
In this study, we reported our experience in TAE using
PVA particles and micro-coils for massive polycystic liver in
ADPKD patients. In two out of three patients, total liver
volumes and cyst volumes were reduced substantially by
TAE after one year, and TAE improved quality of life for the
patients in ways of improving nutritional status and allevi-
ating symptoms from enlarged hepatic cysts.
Massive polycystic liver disease seems female-predominant
with known risk factors of multiple pregnancies, use of oral
contraceptives and estrogen replacement therapy, suggest-
ing a direct role of estrogen exposure in hepatic cyst growth
(9). However, positive correlation between estrogen level and
prevalence of hepatic cysts are not proven yet (1, 2).
There have been few effective treatments for symptomatic
polycystic liver in ADPKD patients: cyst aspiration with
sclerosis, laparoscopic or open cystectomy, segmental hepa-
tectomy, and hepatic transplantation (2, 10). Cyst aspiration
with sclerosis can be effective for a few large liver cysts, but
patients with multiple small cysts cannot benefit from these
therapies (3, 4). Hepatic transplantation can be an effective
way to treat symptomatic polycystic liver (6), but, in Korea,
there are not many cadaveric donors. 
Liver is ordinarily divided into 8 segments according to the
Couinaud classification, and each segment is supplied from
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No.
Embolized 
hepatic 
segments
No. of 
coils
Intrahepatic arteries
1 S1, S3, S4,  Ventrolateral branch of left hepatic artery 14
S5, S8 Middle hepatic artery
Anteroinferior branch of right hepatic artery
Anterosuperior branch of right hepatic artery
2 S4, S5, S6,  Middle hepatic artery 17
S7, S8 Anteroinferior branch of right hepatic artery
Posteroinferior branch of right hepatic artery
Posterosuperior branch of right hepatic artery
Anterosuperior branch of right hepatic artery
3 S1, S5, S6,  Anteroinferior branch of right hepatic artery 24
S7, S8 Posteroinferior branch of right hepatic artery
Posterosuperior branch of right hepatic artery
Anterosuperior branch of right hepatic artery
Table 3. Embolized hepatic segments and blood supply
S1, Caudate lobe; S2, Dorsolateral segment; S3, Ventrolateral segment;
S4, Medial segment; S5, Anteroinferior segment; S6, Posteroinferior seg-
ment; S7, Posterosuperior segment; S8, Anterosuperior segment.
Fig. 3. (A) Total liver volume before and after hepatic TAE. Total liver volume at 12 month after hepatic TAE decreased in all patients, show-
ing as much as 33% reduction from pretreatment liver volume. (B) Intra-hepatic cyst volume before and after hepatic TAE. Total volume of
hepatic cysts decreased in two cases, showing as much as 35% reduction from pretreatment cyst volume.
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2both hepatic artery and portal vein. In polycystic liver, most
portal veins are replaced by cysts and most of blood supplies
come from hepatic arteries (6). Therefore, embolization of
super-selected hepatic artery for cystic segments can be an
easy and effective way to relieve symptoms from enlarged
hepatic cysts without serious adverse events.
We designed a pilot study to evaluate the effectiveness and
complications of hepatic TAE for polycystic liver in ADPKD
patients. Four patients were enrolled in the study, and we
measured the liver and hepatic cyst volumes before and after
treatment. Hepatic TAE was super-selectively performed using
platinum coils and PVA particles. Takei et al. reported use
of coils for hepatic TAE to treat symptomatic polycystic liver
(3). In addition, we used PVA particles for more distal em-
bolization before deployment of coils to occlude the target
arteries completely and to reduce the incidence of collateral-
ization. 
Coils have an advantage of being precisely positioned under
fluoroscopic visualization. But, collateralization is a poten-
tial disadvantage of coil embolization, and it can result in
persistent blood flow into the vascular territory of the embo-
lized vessel, reducing therapeutic efficacy. PVA particle is
also considered as a permanent embolic agent because of a
low incidence in recanalization of the embolized vessels and
of its small size that can be delivered more distally than coils
in the target artery.
We did not enroll more than four patients in this pilot
study because symptoms from massive polycystic liver had
not been improved in a short time after TAE and treatment-
related immediate complications seemed more severe than
anticipated when we analyzed the results one month after
TAE. In the previous study of Ubara et al., no serious com-
plications were reported after hepatic TAE (3). However, in
our study, immediate complications were severe enough to
stop us from recruiting more patients. 
The etiology of post-embolization syndrome is not fully
understood, but it may be caused by a combination of tissue
ischemia and an inflammatory response to embolization.
Moderate to severe epigastric pain, fever, severe nausea and
vomiting can be an early presentation of post-embolization
syndrome, and it can be partly related with the additional
use of PVA particles for embolization. Histologically, PVA
causes intra-luminal thrombosis associated with an inflamma-
tory reaction, with subsequent organization of the thrombus.
Embolization with both PVA particles and coils can cause
more severe post-embolization syndrome than coil emboliza-
tion. Therefore, further studies are needed to evaluate the most
effective embolization materials and techniques to increase
the therapeutic efficacy and to reduce the early complications.
Despite early complications, hepatic TAE in selected pati-
ents was effective and safe on a long-term follow-up. In two
out of three patients, the total liver volumes decreased by 10%
and 33%, and the cyst volumes decreased by 11.4% and
47.7%. There was no treatment-related morbidity or mor-
tality at one year after TAE. Takei et al. performed hepatic
TAE in 30 patients and reported that total liver volume and
intra-hepatic cyst volume decreased from 7,882±2,916 and
6,677±2,978 to 6,041±2,282 and 4,625±2,299 cm3 (6).
The fractions of remaining liver volume and intra-hepatic
cyst volume were 78.8±17.6% and 70.4±20.9%. Our
results were comparable to those in the previous study. 
In conclusion, we suggest that hepatic TAE can be effective
and safe way to treat symptomatic polycystic liver in select-
ed patients. There should be a large, randomized study to
define the effectiveness and complications of hepatic TAE.
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